First-quarter 2025 Rezdiffra™ (resmetirom) net sales of $137.3 million As of March 31, 2025, more than 17,000 patients on Rezdiffra Two-year compensated MASH cirrhosis (F4c) data from MAESTRO-NAFLD-1 trial selected as oral late-breaker at EASL Congress (May 7-10)Appointed David Soergel, M.D., to Chief Medical Officer; Rebecca Taub, M.D., named Senior Scientific and Medical Advisor Appointed Jacqualyn Fouse, Ph.D., to Board of DirectorsReports cash, cash equivalents, restricted cash and marketable securities ...

CONSHOHOCKEN, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction- associated steatohepatitis (MASH), today announced six presentations at the upcoming European Association for the Study of the Liver (EASL) Congress, taking place from May 7-10, 2025, in Amsterdam, the Netherlands. Madrigal will share detailed two-year data from the open-label compensated MASH cirrhosis (F4c) arm ...

Core Viewpoint - Madrigal Pharmaceuticals is set to release its first-quarter 2025 financial results on May 1, 2025, before the U.S. markets open [1] Company Overview - Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) focuses on developing novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with significant unmet medical needs [3] - The company's primary medication, Rezdiffra (resmetirom), is a once-daily oral THR-β agonist targeting the underlying causes of MASH and is the first FDA-approved treatment for MASH with moderate to advanced fibrosis (F2 to F3 stages) [3] - An ongoing Phase 3 trial is assessing Rezdiffra for treating compensated MASH cirrhosis (F4c stage) [3] Upcoming Events - Following the financial results announcement, Madrigal's management will host a live webcast at 8 a.m. Eastern Time to discuss the financial and operational results [2] - The webcast will be accessible via the Investor Relations section of the Madrigal Pharmaceuticals website, with a recommendation for participants to register at least 15 minutes in advance [2]

CONSHOHOCKEN, Pa., April 16, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that Rebecca Taub, M.D., the company's founder, Chief Medical Officer, and President of Research & Development (R&D), will transition to the role of Senior Scientific and Medical Advisor. Dr. Taub will continue to serve on Madrigal's Board of Directors. Succeeding ...

Company Overview - Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) [5] - The company's medication, Rezdiffra (resmetirom), is the first and only FDA-approved treatment for MASH with moderate to advanced fibrosis [6] Leadership Transition - Rebecca Taub, M.D., the founder and Chief Medical Officer, will transition to Senior Scientific and Medical Advisor while continuing on the Board of Directors [1] - David Soergel, M.D., has been appointed as the new Executive Vice President and Chief Medical Officer, effective April 21, 2025 [1] Achievements and Future Plans - Under Dr. Taub's leadership, Madrigal achieved the milestone of developing Rezdiffra, the first FDA-approved medicine for MASH, providing hope to patients [2][3] - Dr. Soergel brings over 20 years of experience in drug development for metabolic and cardiovascular diseases, which aligns with the company's goal to expand its pipeline beyond Rezdiffra [3][4] Company Growth - Madrigal has grown from a small team of fewer than 10 R&D professionals to a commercial-stage biopharma company with over 500 employees across the U.S. and Europe [3]

It has been about a month since the last earnings report for Madrigal (MDGL) . Shares have added about 0.5% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Madrigal due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.How Have Estimates Been Moving Since Then?It turns o ...

Fred Craves, Ph.D. to retire from Madrigal’s Board of Directors in July 2025 CONSHOHOCKEN, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced it has appointed Jacqualyn (“Jackie”) Fouse, Ph.D. to its Board of Directors. Fred Craves, Ph.D. is retiring from the Board in July 2025. Julian Baker, Chairman of the Board of Directors, s ...

Madrigal Pharmaceuticals (MDGL) reported fourth-quarter 2024 loss of $2.71 per share, narrower than the Zacks Consensus Estimate of a loss of $4.12. In the year-ago quarter, the company had incurred a loss of $5.68 per share.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.During the quarter, the company generated total revenues of $103.3 million entirely from product sales of its metabolic dysfunction-associated steatohepatitis (MASH) drug Rezdiffra (resmetirom), which was approved la ...

If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there.Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL ) announced its Q4 and full-year 2024 earnings earlier today, and the market's initial response has been positive, with shares ...

Shares of Madrigal Pharmaceuticals (MDGL 17.62%) were soaring 15.2% higher as of 11:05 a.m. ET on Wednesday. The big gain came after the small biopharmaceutical company announced its fourth-quarter and full-year 2024 results before the market opened.Madrigal reported fourth-quarter revenue of $103.3 million, all of which stemmed from sales of Rezdiffra, the first drug approved for treating metabolic dysfunction-associated steatohepatitis (MASH). The company posted a net loss in Q4 of $59.4 million, or $2.71 ...